Russell Investments Group’s Forte Biosciences FBRX Stock Holding History

Russell Investments Group’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.5M	Sell	70,409 -21,363	-23%	-$507K	﹤0.01%	2243
2026 Q1	$2.38M	Buy	+91,772	New	+$2.64M	﹤0.01%	1785
2024 Q4	–	Sell	-18	Closed	-$100	–	3728
2024 Q3	$100	Hold	18	–	–	﹤0.01%	3663
2024 Q2	$243	Hold	18	–	–	﹤0.01%	3540
2024 Q1	$317	Hold	18	–	–	﹤0.01%	3253
2023 Q4	$372	Hold	18	–	–	﹤0.01%	3142
2023 Q3	$299	Hold	18	–	–	﹤0.01%	3447
2023 Q2	$471	Hold	18	–	–	﹤0.01%	3364
2023 Q1	$457	Hold	18	–	–	﹤0.01%	3147
2022 Q4	$453	Hold	18	–	–	﹤0.01%	2883
2022 Q3	$0	Hold	18	–	–	﹤0.01%	2925
2022 Q2	$0	Hold	18	–	–	﹤0.01%	2913
2022 Q1	$0	Hold	18	–	–	﹤0.01%	2805
2021 Q4	$0	Hold	18	–	–	﹤0.01%	3023
2021 Q3	$1K	Hold	18	–	–	﹤0.01%	3021
2021 Q2	$15K	Hold	18	–	–	﹤0.01%	3181
2021 Q1	$15K	Buy	+18	New	+$14.7K	﹤0.01%	3069
2019 Q1	–	Sell	-79	Closed	-$242K	–	2937
2018 Q4	$242K	Sell	79 -49	-38%	-$211K	﹤0.01%	2553
2018 Q3	$747K	Sell	128 -88	-41%	-$335K	﹤0.01%	2229
2018 Q2	$757K	Hold	216	–	–	﹤0.01%	2259
2018 Q1	$961K	Buy	216 +112	+108%	+$519K	﹤0.01%	2218
2017 Q4	$425K	Buy	+104	New	+$415K	﹤0.01%	2485

Other funds holding FBRX

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Russell Investments Group's FBRX Position: Q2 2026 in Review

Russell Investments Group reduced its Forte Biosciences (FBRX) stake by 23% in Q2 2026, selling an estimated $507K and leaving 70,409 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2243.

Russell Investments Group first reported a position in FBRX in Q4 2017 and has held it in 22 quarters since. The position peaked at $2.38M in Q1 2026. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

Russell Investments Group held 70,409 shares of Forte Biosciences worth $1.5M as of Q2 2026.
Russell Investments Group sold 21,363 Forte Biosciences shares in Q2 2026, an estimated $507K.
Forte Biosciences made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2243 holding.
Russell Investments Group first reported a position in Forte Biosciences in Q4 2017 and has held it in 22 quarters since.
Russell Investments Group's Forte Biosciences position peaked at $2.38M in Q1 2026.
86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.